Article info

Download PDFPDF

Original research
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity

Authors

  • Dawei Chen Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Hampartsoum B Barsoumian Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Grant Fischer Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, United States Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, United States PubMed articlesGoogle scholar articles
  • Liangpeng Yang Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Vivek Verma Department of Radiation oncology, Allegheny General Hospital, Pittsburgh, United States PubMed articlesGoogle scholar articles
  • Ahmed I Younes Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Yun Hu Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Fatemeh Masropour Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Katherine Klein Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Christopher Vellano Translational Research to Advance Therapeutics and Innovation in Oncology Platform, The University of Texas MD Anderson Cancer Center, Houston, United States Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, United States PubMed articlesGoogle scholar articles
  • Joseph Marszalek Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States PubMed articlesGoogle scholar articles
  • Michael Davies Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, United States Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Houston, TX, United States PubMed articlesGoogle scholar articles
  • Maria Angelica Cortez Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • James Welsh Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dawei Chen; chendawei0505{at}yahoo.com; James Welsh; JWelsh{at}mdanderson.org
View Full Text

Citation

Chen D, Barsoumian HB, Fischer G, et al
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity

Publication history

  • Accepted April 23, 2020
  • First published June 24, 2020.
Online issue publication 
June 24, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.